Hakutulokset - Yinglu Zhou

  • Näytetään 1 - 8 yhteensä 8 tuloksesta
Tarkenna hakua
  1. 1
    Deciphering the role of KLRB1: a novel prognostic indicator in hepatocellular carcinoma

    Deciphering the role of KLRB1: a novel prognostic indicator in hepatocellular carcinoma Tekijä Siting Fang, Yinglu Zhou

    Julkaistu 2024
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Antitumor effects of baicalin on ovarian cancer cells through induction of cell apoptosis and inhibition of cell migration in vitro

    Antitumor effects of baicalin on ovarian cancer cells through induction of cell apoptosis and inhibition of cell migration in vitro Tekijä Chen Gao, Yinglu Zhou, Huatao Li, Cong Xia, Zhongling Jiang, Xin Wang, Rongfeng Cao, Wenru Tian

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Cytotoxic and chemosensitization effects of Scutellarin from traditional Chinese herb Scutellaria altissima L. in human prostate cancer cells

    Cytotoxic and chemosensitization effects of Scutellarin from traditional Chinese herb Scutellaria altissima L. in human prostate cancer cells Tekijä Chen Gao, Yinglu Zhou, Zhongling Jiang, Zhao Yuan, Dongjun Zhang, Cong Xia, Rongfeng Cao, Huatao Li, Wenru Tian

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Pre-existing Castration-resistant Prostate Cancer–like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy

    Pre-existing Castration-resistant Prostate Cancer–like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy Tekijä Qing Cheng, William Butler, Yinglu Zhou, Hong Zhang, Lu Tang, Kathryn Perkinson, Xufeng Chen, Xiaoyin “Sara” Jiang, Shannon J. McCall, Brant A. Inman, Jiaoti Huang

    Julkaistu 2022
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

    Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance Tekijä Aishath Naeem, Filippo Utro, Qing Wang, Justin Cha, Mauno Vihinen, Stephen P. Martindale, Yinglu Zhou, Yue Ren, Svitlana Tyekucheva, Annette S. Kim, Stacey M. Fernandes, Gordon Saksena, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P. Danysh, Kara Slowik, Raquel A. Jacobs, Matthew S. Davids, James A. Lederer, Rula Zain, Smith Rjh, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance

    Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance Tekijä Su Deng, Choushi Wang, Yunguan Wang, Yaru Xu, Xiaoling Li, Nickolas A. Johnson, Atreyi Mukherji, U‐Ging Lo, Lingfan Xu, Julisa Gonzalez, Lauren A. Metang, Jianfeng Ye, Carla R. Tirado, Kathia E. Rodarte, Yinglu Zhou, Zhiqun Xie, Carlos Arana, Valli Annamalai, Xihui Liu, Donald J. Vander Griend, Douglas W. Strand, Jer‐Tsong Hsieh, Bo Li, Ganesh V. Raj, Tao Wang, Ping Mu

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Characteristics and Outcomes of Patients with Double Refractory and Double Exposed Chronic Lymphocytic Leukemia

    Characteristics and Outcomes of Patients with Double Refractory and Double Exposed Chronic Lymphocytic Leukemia Tekijä Jeongsook Yoon, Yinglu Zhou, Mariia Mikhaleva, Daniel Choi, Stacey M. Fernandes, Philippe Armand, Amy C. Bessnow, Jennifer L. Crombie, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Reid W. Merryman, Oreofe O. Odejide, Erin M. Parry, David Qualls, Christine E. Ryan, Aswin Sekar, Jacob D. Soumerai, Jon Arnason, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn

    Julkaistu 2025
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer

    Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer Tekijä Yanjing Li, Yiping He, William Butler, Lingfan Xu, Yan Chang, Kefeng Lei, Hong Zhang, Yinglu Zhou, Allen C. Gao, Qingfu Zhang, Daniel Taylor, Donghui Cheng, Suzette Farber-Katz, Rachid Karam, Tyler Landrith, Bing Li, Sitao Wu, Vickie Hsuan, Qing Yang, Hailiang Hu, Xufeng Chen, Melissa Flowers, Shannon J. McCall, John K. Lee, B. Smith, Jung Wook Park, Andrew S. Goldstein, Owen N. Witte, Qianben Wang, Matthew B. Rettig, Andrew J. Armstrong, Qing Cheng, Jiaoti Huang

    Julkaistu 2019
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: